CD70靶向[18F]RCCB6免疫PET/CT在鼻咽癌患者中的概念验证研究
该研究分析80例鼻咽癌标本中CD70表达,并在25例鼻咽癌患者中评估CD70靶向[18F]RCCB6免疫PET/CT的诊断效能并与18F-FDG PET/CT比较。CD70在72例(90%)标本中阳性表达,[18F]RCCB6检测淋巴结转移灵敏度高于18F-FDG(100% vs 90%,P=0.031),对颅底侵犯和骨转移评估更优。结论认为CD70是鼻咽癌的有力生物标志物,[18F]RCCB6免疫PET/CT可精准定位CD70表达并提升原发、转移和复发鼻咽癌的诊断。
要点
- 80例鼻咽癌标本中CD70阳性表达72例(90%),表达水平与EBV滴度(rs=0.437,P<0.001)及N分期(P=0.006)相关。
- 15例早期鼻咽癌中,[18F]RCCB6免疫PET/CT原发灶检出率100%,局部淋巴结转移检出率93%(75/81)。
- [18F]RCCB6检测淋巴结转移灵敏度高于18F-FDG(100%[58/58] vs 90%[52/58],P=0.031),颅底侵犯摄取更高(7.25 vs 5.95,P=0.025)。
核心结论
- CD70是鼻咽癌的有力生物标志物。
- [18F]RCCB6免疫PET/CT可精准定位CD70表达,提升原发、转移和复发鼻咽癌的诊断,在检测颅底侵犯和转移方面优于18F-FDG。
研究设计与样本
- 分析80例存档鼻咽癌标本的CD70表达并与临床病理特征相关。
- 在25例鼻咽癌患者中使用CD70靶向[18F]RCCB6免疫PET/CT评估诊断效能,并与18F-FDG PET/CT比较。
主要发现
- 80例鼻咽癌标本中CD70阳性表达72例(90%),表达水平与EBV滴度强相关(rs=0.437;P<0.001),与N分期相关(P=0.006)。
- 15例早期鼻咽癌患者中,[18F]RCCB6免疫PET/CT原发肿瘤检出率100%,局部淋巴结转移检出率93%(75/81)。
- [18F]RCCB6摄取与CD70表达良好相关。
- 头对头比较中,[18F]RCCB6检测淋巴结转移灵敏度高于18F-FDG(100%[58/58] vs 90%[52/58];P=0.031)。
- [18F]RCCB6对原发灶和大多数远处转移的检出能力与18F-FDG相当(100%),颅底侵犯摄取高于18F-FDG(7.25 vs 5.95;P=0.025)。
关键数值与推荐
- CD70阳性表达:72/80例(90%)。
- CD70表达与EBV滴度相关系数rs=0.437(P<0.001),与N分期P=0.006。
- 早期鼻咽癌原发灶检出率100%,局部淋巴结转移检出率93%(75/81)。
- 淋巴结转移检测灵敏度:[18F]RCCB6 100%(58/58)vs 18F-FDG 90%(52/58),P=0.031。
- 颅底侵犯摄取:[18F]RCCB6 7.25 vs 18F-FDG 5.95,P=0.025。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD70 has emerged as a promising biomarker for nasopharyngeal carcinoma (NPC). This study investigated CD70 expression patterns in NPC specimens and evaluated the diagnostic potential of CD70-targeted [18F]RCCB6 immuno-PET/CT in patients with NPC. Methods: CD70 expression was analyzed in 80 archived NPC specimens and correlated with clinical and pathologic features. Using [18F]RCCB6, a single-domain antibody-derived tracer specific for human CD70, the diagnostic efficacy of [18F]RCCB6 immuno-PET/CT was assessed in 25 patients with NPC and compared with that of 18F-FDG PET/CT. Results: CD70 was positively expressed in 72 (90%) of 80 NPC specimens, with expression levels strongly correlated with Epstein-Barr virus (EBV) titers (rs = 0.437; P < 0.001) and N-staging (P = 0.006). In all 15 patients with early-stage NPC, [18F]RCCB6 immuno-PET/CT achieved a 100% detection rate of the primary tumor and a 93% detection rate (75/81) of local lymph node metastasis. [18F]RCCB6 uptake correlated well with CD70 expression. In a head-to-head comparison, [18F]RCCB6 demonstrated higher sensitivity than did 18F-FDG in detecting lymph node metastasis (100% [58/58] vs. 90% [52/58], respectively; P = 0.031), and equivalent detection abilities for primary lesions and most distant metastases (100%). Notably, [18F]RCCB6 immuno-PET/CT demonstrated better evaluation of skull-base invasion with a clear border and bone metastases, as indicated by its higher uptake compared with 18F-FDG (7.25 vs. 5.95; P = 0.025). Conclusion: CD70 is a potent biomarker for NPC. [18F]RCCB6 immuno-PET/CT provides precise mapping of CD70 expression and enhances the diagnosis of primary, metastatic, and recurrent NPCs, outperforming 18F-FDG in detecting skull-base invasion and metastases.
引用
- Shi B, Zhang Y, Wu S, et al. CD70-Targeted [18F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study. J Nucl Med. 2025. PMID: 40306966. doi:10.2967/jnumed.125.269585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。